Report Company Directory

Amarillo Biosciences Inc.

• Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board by GlobeNewsWire
• Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics by GlobeNewsWire
• Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications by GlobeNewsWire
• Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement by GlobeNewsWire
• Amarillo Biosciences First-Half 2018 Business Update by GlobeNewsWire
• Weekly Insider Tables: Apr 7, 2018 by InsiderInsights.com
• Weekly Insider Tables: Mar 31, 2018 by InsiderInsights.com
• Weekly Insider Tables: Mar 17, 2018 by InsiderInsights.com
• Daily Insider Ratings Report: Mar 13, 2018 by InsiderInsights.com

Amarillo Gold

• Amarillo Gold Corporation and Lavras Gold Corp. complete arrangement and launch by GlobeNewsWire
• Amarillo acquisition closing and Lavras Gold spinout expected on April 1 by GlobeNewsWire
• Amarillo receives final order from Supreme Court of British Columbia for Plan of Arrangement by GlobeNewsWire
• Amarillo shareholders approve plan of arrangement by GlobeNewsWire
• A year of exploration and development success for Amarillo by GlobeNewsWire
• Amarillo Reminds Shareholders of Proxy Cutoff in Connection with its Special Meeting to Approve Acquisition by Hochschild by GlobeNewsWire
• Amarillo files updated technical report for Posse Gold Project by GlobeNewsWire
• Amarillo files NI 43-101 report for LDS Butiá Gold Prospect by GlobeNewsWire
• Amarillo files Management Information Circular for Meeting to approve acquisition by Hochschild by GlobeNewsWire
• Amarillo discovers new primary gold deposit at Mara Rosa by GlobeNewsWire

Amarin Corporation Plc Sponsored ADR

• Amarin Reports First Quarter 2025 Financial Results by GlobeNewsWire
• Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement by GlobeNewsWire
• Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 by GlobeNewsWire
• Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change by GlobeNewsWire
• Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors by GlobeNewsWire
• Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist by GlobeNewsWire
• New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Ca by GlobeNewsWire
• Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action  by GlobeNewsWire
• Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program by GlobeNewsWire
• Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering by GlobeNewsWire

Amarin Printing & Publishing

• Amarin Corporations Public Company Ltd: 1 director by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research

AMARIN PRINTING & PUBLISHING PUB CO